Recently Added |View All
Video
Roswell Park Set to Open Several New Trials this Year for Innovative CAR T-Cell Therapies
CAR T-cell therapies are the future of cancer treatment and Roswell Park Comprehensive Cancer Center is preparing to open a number of new trials based on research originating here and in partnership with the industry.
News
Phase 3 clinical trial is underway, it will evaluate the potential of combining an investigational drug, the targeted therapy XL092 (brand name Zanzalintinib), with the FDA-approved immunotherapy nivolumab (brand name Opdivo).
Video
Roswell Park Accelerates CAR T-Cell Innovation with Upcoming Trials
Renier Brentjens, MD, PhD, has spent most of his career pioneering research into the development and use of CAR T-cell therapies in the hopes of finding innovative and effective treatments for cancer.
News
Tandem 2025: Roswell Park Team Creates Predictive Model to Inform Care of Lymphoma Patients
Discoveries made by experts from Roswell Park Comprehensive Cancer Center will be featured at an international conference focusing on the latest advances in stem cell transplantation and other cell therapies for blood cancers.
News
Clinical Trial Evaluates Promising Combination Therapy for Metastatic Uveal Melanoma
A combination of two protein kinase inhibitors that has shown promise in patients with metastatic uveal melanoma is being evaluated in a phase 2/3 clinical trial at Roswell Park Comprehensive Cancer Center.
Video
Two New CAR T-cell Therapy Trials Focus on Relapsed Multiple Myeloma
A pair of open and enrolling clinical trials are offering strong preliminary results for patients with relapsed multiple myeloma, says Ehsan Malek, MD, Director of Multiple Myeloma Translational Research at Roswell Park Comprehensive Cancer Center.
Video
New CAR T Clinical Trials Underway at Roswell Park for Solid Tumor, Non-cancerous Diseases
While the focus and promise of CAR T-cell therapies has long been on liquid tumors and hematologic malignancies, new trials under way at Roswell Park Comprehensive Cancer Center are expanding the applications of immunotherapy to include other diseases.
News
Roswell Park Comprehensive Cancer Center is moving the science forward by offering clinical trials aimed at extending the benefits of those therapies to patients with all types of solid tumors.
News
Can NST-628 Fill the Treatment Void For Advanced Tumors with RAS or RAF Mutations?
A phase 1 clinical trial underway at Roswell Park Comprehensive Cancer Center will evaluate the potential of a “molecular glue” to treat MAPK pathway-mutated advanced solid tumors in patients who have exhausted standard treatment options.
This site is intended for healthcare professionals
Download our free mobile app — exclusively for physicians and physician offices — for direct access to a complete, up-to-date directory of Roswell Park physicians wherever you go. Email or call to refer a patient or ask a question with a click of a button.
BROADCASTMED